An update on weight-loss drugs semaglutide (Wegovy) and tirzepatide (Mounjaro), who should avoid them and what the alternatives are
Weight-loss injections such as Wegovy and Mounjaro are gaining more attention as pharmacological ways to combat obesity. The UK government has even suggested they could help get some unemployed people back into work. Here’s what nurses need to know.
Nursing Standard. 39, 12, 12-13. doi: 10.7748/ns.39.12.12.s5
or
Alternatively, you can purchase access to this article for the next seven days. Buy now
Are you a student? Our student subscription has content especially for you.
Find out more
